Jiaqiang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiaqiang Liu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Kaili Lin
Department of Oral & Cranio-Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, 200011, China
8 shared publications Ziyang Liu
5 shared publicationsWeiqi Li
4 shared publicationsAn Lao
3 shared publicationsDejian Li
Department of Orthopedics, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201301, China
3 shared publicationsJiaqing Wu
Department of Oral and Cranio-Maxillofacial Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai 200011, China
3 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Multifunctional hydrogel based on metal-phenolic network-coated Nb₂C nanosheets for diabetic bone regeneration via microenvironment remodeling
Diabetes mellitus (DM)-related bone defects remain a major clinical challenge, as persistent oxidative stress, chronic inflammation, and cellular senescence collectively impair vascularized bone regeneration, while current treatments lack integrated strategies to address these interconnected pathological processes. Herein, we developed a multifunctional hydrogel system loaded with tannic acid–zinc ion-coated Nb₂C nanosheets (Nb₂C@TA-Zn, NTZ) within a GelMA scaffold. The coordination of tannic acid and zinc ions on Nb₂C not only stabilizes the nanosheet structure but also enhances its biological functions, enabling responsive release and sustained microenvironment regulation under diabetic conditions. In vitro experiments demonstrated that NTZ alleviates senescence of bone marrow mesenchymal stem cells (BMSCs) under oxidative stress by modulating the AKT/MDM2/p53 signaling axis, thereby restoring their osteogenic capacity and pro-angiogenic paracrine functions. Concurrently, NTZ promotes macrophage polarization toward the M2 phenotype, contributing to the maintenance of immune homeostasis and the construction of a pro-regenerative osteoimmune microenvironment. In an in vivo diabetic calvarial defect model, NTZ-loaded hydrogel synergistically suppressed local inflammation and cellular senescence, ultimately achieving efficient vascularized bone regeneration with favorable biosafety. Collectively, this study provides a simple and effective therapeutic strategy for DM bone defect repair through multifunctional synergistic regulation.
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultifunctional hydrogel based on metal-phenolic network-coated Nb₂C nanosheets for diabetic bone regeneration via microenvironment remodeling
Diabetes mellitus (DM)-related bone defects remain a major clinical challenge, as persistent oxidative stress, chronic inflammation, and cellular senescence collectively impair vascularized bone regeneration, while current treatments lack integrated strategies to address these interconnected pathological processes. Herein, we developed a multifunctional hydrogel system loaded with tannic acid–zinc ion-coated Nb₂C nanosheets (Nb₂C@TA-Zn, NTZ) within a GelMA scaffold. The coordination of tannic acid and zinc ions on Nb₂C not only stabilizes the nanosheet structure but also enhances its biological functions, enabling responsive release and sustained microenvironment regulation under diabetic conditions. In vitro experiments demonstrated that NTZ alleviates senescence of bone marrow mesenchymal stem cells (BMSCs) under oxidative stress by modulating the AKT/MDM2/p53 signaling axis, thereby restoring their osteogenic capacity and pro-angiogenic paracrine functions. Concurrently, NTZ promotes macrophage polarization toward the M2 phenotype, contributing to the maintenance of immune homeostasis and the construction of a pro-regenerative osteoimmune microenvironment. In an in vivo diabetic calvarial defect model, NTZ-loaded hydrogel synergistically suppressed local inflammation and cellular senescence, ultimately achieving efficient vascularized bone regeneration with favorable biosafety. Collectively, this study provides a simple and effective therapeutic strategy for DM bone defect repair through multifunctional synergistic regulation.
- Open Access
- 22 December 2025
- Published by American Association for the Advancement of Science (AAAS) in BME Frontiers
- Vol. 6
Prussian Blue Nanoparticles Promoting Diabetic Bone Regeneration via Mitochondrial Recovery
Objective: This work aims to develop Prussian blue (PB) nanoparticles that mitigate bone marrow mesenchymal stem cell (BMSC) senescence and alleviate bone loss in type 2 diabetes (T2D). Impact Statement: PB nanozymes are established as a targeted therapeutic strategy for maintaining bone quality in T2D—addressing an unmet clinical need through innovative nanomaterial design. Introduction: Diabetes is associated with a higher risk of fractures through distinct mechanisms. Elevated blood sugar levels and excessive nutrition in T2D trigger reactive oxygen species (ROS) overproduction that impairs mitochondrial function, induces BMSC senescence, and compromises osteogenic potential. Engineered as artificial enzyme counterparts, nanozymes effectively eliminate ROS while circumventing the inherent constraints of natural antioxidant enzymes. Methods: PB nanoparticles were synthesized and fully characterized. BMSCs treated with high glucose plus palmitate–bovine serum albumin served as the diabetic cell model. The nanoparticles were evaluated for their capacity to scavenge ROS, modulate mitochondrial function, counteract cellular senescence, and restore osteogenic potential. Finally, their ability to attenuate bone loss was verified in a T2D mouse model. Results: We demonstrated that PB nanoparticles efficiently scavenge ROS, rebalance mitochondrial dynamics by up-regulating fusion proteins and down-regulating fission proteins, and restore membrane potential. These actions suppress BMSC senescence and revive osteogenic capacity, culminating in substantial attenuation of T2D-associated bone loss in vivo. Conclusion: These findings introduce a promising and innovative approach for managing bone quality in patients with T2D.
- 22 December 2025
- Published by American Association for the Advancement of Science (AAAS) in BME Frontiers
- Vol. 6
Open AccessPrussian Blue Nanoparticles Promoting Diabetic Bone Regeneration via Mitochondrial Recovery
Objective: This work aims to develop Prussian blue (PB) nanoparticles that mitigate bone marrow mesenchymal stem cell (BMSC) senescence and alleviate bone loss in type 2 diabetes (T2D). Impact Statement: PB nanozymes are established as a targeted therapeutic strategy for maintaining bone quality in T2D—addressing an unmet clinical need through innovative nanomaterial design. Introduction: Diabetes is associated with a higher risk of fractures through distinct mechanisms. Elevated blood sugar levels and excessive nutrition in T2D trigger reactive oxygen species (ROS) overproduction that impairs mitochondrial function, induces BMSC senescence, and compromises osteogenic potential. Engineered as artificial enzyme counterparts, nanozymes effectively eliminate ROS while circumventing the inherent constraints of natural antioxidant enzymes. Methods: PB nanoparticles were synthesized and fully characterized. BMSCs treated with high glucose plus palmitate–bovine serum albumin served as the diabetic cell model. The nanoparticles were evaluated for their capacity to scavenge ROS, modulate mitochondrial function, counteract cellular senescence, and restore osteogenic potential. Finally, their ability to attenuate bone loss was verified in a T2D mouse model. Results: We demonstrated that PB nanoparticles efficiently scavenge ROS, rebalance mitochondrial dynamics by up-regulating fusion proteins and down-regulating fission proteins, and restore membrane potential. These actions suppress BMSC senescence and revive osteogenic capacity, culminating in substantial attenuation of T2D-associated bone loss in vivo. Conclusion: These findings introduce a promising and innovative approach for managing bone quality in patients with T2D.
- 9 September 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (1) , 170-192
Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles
- 9 September 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (1) , 170-192
Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles
- 29 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123656
Senescence-regulating agents remodel mesenchymal stem cell-schwann cell circuitry for diabetic bone regeneration
- 29 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123656
Senescence-regulating agents remodel mesenchymal stem cell-schwann cell circuitry for diabetic bone regeneration
- Top Cited Papers
- 1 July 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (28) , 36077-36094
ZIF-8-based Nanoparticles for Inflammation Treatment and Oxidative Stress Reduction in Periodontitis
Periodontitis, an inflammatory bone resorption disease associated with dental plaque, poses significant challenges for effective treatment. In this study, we developed Mino@ZIF-8 nanoparticles inspired by the periodontal microenvironment and the unique properties of zeolitic imidazolate framework 8, aiming to address the complex pathogenesis of periodontitis. Transcriptome analysis revealed the active engagement of Mino@ZIF-8 nanoparticles in innate and adaptive inflammatory host defense and cellular metabolic remodeling. Through sustained release of the anti-inflammatory and antibacterial agent minocycline hydrochloride (Mino) and the generation of Zn2+ with pro-antioxidant effects during degradation, Mino@ZIF-8 nanoparticles synergistically alleviate inflammation and oxidative damage. Notably, our study focuses on the pivotal role of zinc ions in mitochondrial oxidation protection. Under lipopolysaccharide (LPS) stimulation, periodontal ligament cells undergo a metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis, leading to reduced ATP production and increased reactive oxygen species levels. However, Zn2+ effectively rebalances the glycolysis-OXPHOS imbalance, restoring cellular bioenergetics, mitigating oxidative damage, rescuing impaired mitochondria, and suppressing inflammatory cytokine production through modulation of the AKT/GSK3β/NRF2 pathway. This research not only presents a promising approach for periodontitis treatment but also offers novel therapeutic opportunities for zinc-containing materials, providing valuable insights into the design of biomaterials targeting cellular energy metabolism regulation.
- 1 July 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (28) , 36077-36094
Top Cited PapersZIF-8-based Nanoparticles for Inflammation Treatment and Oxidative Stress Reduction in Periodontitis
Periodontitis, an inflammatory bone resorption disease associated with dental plaque, poses significant challenges for effective treatment. In this study, we developed Mino@ZIF-8 nanoparticles inspired by the periodontal microenvironment and the unique properties of zeolitic imidazolate framework 8, aiming to address the complex pathogenesis of periodontitis. Transcriptome analysis revealed the active engagement of Mino@ZIF-8 nanoparticles in innate and adaptive inflammatory host defense and cellular metabolic remodeling. Through sustained release of the anti-inflammatory and antibacterial agent minocycline hydrochloride (Mino) and the generation of Zn2+ with pro-antioxidant effects during degradation, Mino@ZIF-8 nanoparticles synergistically alleviate inflammation and oxidative damage. Notably, our study focuses on the pivotal role of zinc ions in mitochondrial oxidation protection. Under lipopolysaccharide (LPS) stimulation, periodontal ligament cells undergo a metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis, leading to reduced ATP production and increased reactive oxygen species levels. However, Zn2+ effectively rebalances the glycolysis-OXPHOS imbalance, restoring cellular bioenergetics, mitigating oxidative damage, rescuing impaired mitochondria, and suppressing inflammatory cytokine production through modulation of the AKT/GSK3β/NRF2 pathway. This research not only presents a promising approach for periodontitis treatment but also offers novel therapeutic opportunities for zinc-containing materials, providing valuable insights into the design of biomaterials targeting cellular energy metabolism regulation.
- Top Cited Papers
Functionalized Metal–Organic Framework‐Modified Hydrogel That Breaks the Vicious Cycle of Inflammation and ROS for Repairing of Diabetic Bone Defects
The regeneration of diabetic bone defects remains challenging. Hyperglycemia causes inflammation state and excessive reactive oxygen species (ROS) during bone regeneration period. These two effects reinforce one another and create an endless loop that is also accompanied by mitochondrial dysfunction. However, there is still no effective and inclusive method targeting at the two aspects and breaking the vicious cycle. Herein, nanoparticles‐Met@ZIF‐8(metformin loaded zeolitic imidazolate frameworks) modified hydrogel that is capable of releasing metformin and Zn elements are constructed. This hydrogel treats hyperglycemia while also controlling mitochondrial function, reducing inflammation, and restoring homeostasis. In addition, the synergetic effect from metformin and Zn ions inhibits ROS‐inflammation cascade generation and destroys the continuous progress by taking effects in both ROS and inflammation and further keeping organelles’ homeostasis. Furthermore, with the recovery of mitochondria and breakdown of the ROS‐inflammation cascade cycle, osteogenesis under a diabetic microenvironment is enhanced in vivo and in vitro. In conclusion, the study provides critical insight into the biological mechanism and potential therapy for diabetic bone regeneration.
Top Cited PapersFunctionalized Metal–Organic Framework‐Modified Hydrogel That Breaks the Vicious Cycle of Inflammation and ROS for Repairing of Diabetic Bone Defects
The regeneration of diabetic bone defects remains challenging. Hyperglycemia causes inflammation state and excessive reactive oxygen species (ROS) during bone regeneration period. These two effects reinforce one another and create an endless loop that is also accompanied by mitochondrial dysfunction. However, there is still no effective and inclusive method targeting at the two aspects and breaking the vicious cycle. Herein, nanoparticles‐Met@ZIF‐8(metformin loaded zeolitic imidazolate frameworks) modified hydrogel that is capable of releasing metformin and Zn elements are constructed. This hydrogel treats hyperglycemia while also controlling mitochondrial function, reducing inflammation, and restoring homeostasis. In addition, the synergetic effect from metformin and Zn ions inhibits ROS‐inflammation cascade generation and destroys the continuous progress by taking effects in both ROS and inflammation and further keeping organelles’ homeostasis. Furthermore, with the recovery of mitochondria and breakdown of the ROS‐inflammation cascade cycle, osteogenesis under a diabetic microenvironment is enhanced in vivo and in vitro. In conclusion, the study provides critical insight into the biological mechanism and potential therapy for diabetic bone regeneration.
- 6 December 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (5) , 974-984
A sustained-release PDGF-BB nanocomposite hydrogel for DM-associated bone regeneration
Regeneration of bone tissue in the environment of diabetes mellitus (DM) remains one of the clinical challenges, with malfunction of stem cells in a high-glucose microenvironment being the primary obstacle. We designed an injectable sustained-release PDGF-BB nanocomposite hydrogel. PDGF-BB, a star molecule for treating various complications of DM, was used for the first time for DM-associated bone regeneration, and we showed that it restored stem cell proliferation and migration and facilitated osteogenesis inhibition under high glucose stimulation by activating ERK and AKT pathways. To address the requirements for continuous PDGF-BB release in GelMA while also increasing mechanical strength, nanoclay LAPONITE® was added, which may still exhibit pro-osteogenic activity in diabetic environments by releasing bioactive ions (Si4+, Mg2+, and Li+). This injectable hydrogel heals calvarial lesions successfully in diabetic rats and has the potential to be used as a direct and effective tool for treating diabetic patients.
- 6 December 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (5) , 974-984
A sustained-release PDGF-BB nanocomposite hydrogel for DM-associated bone regeneration
Regeneration of bone tissue in the environment of diabetes mellitus (DM) remains one of the clinical challenges, with malfunction of stem cells in a high-glucose microenvironment being the primary obstacle. We designed an injectable sustained-release PDGF-BB nanocomposite hydrogel. PDGF-BB, a star molecule for treating various complications of DM, was used for the first time for DM-associated bone regeneration, and we showed that it restored stem cell proliferation and migration and facilitated osteogenesis inhibition under high glucose stimulation by activating ERK and AKT pathways. To address the requirements for continuous PDGF-BB release in GelMA while also increasing mechanical strength, nanoclay LAPONITE® was added, which may still exhibit pro-osteogenic activity in diabetic environments by releasing bioactive ions (Si4+, Mg2+, and Li+). This injectable hydrogel heals calvarial lesions successfully in diabetic rats and has the potential to be used as a direct and effective tool for treating diabetic patients.